The Inhibitory Quotient in Tipranavir/Ritonavir (July 14, 2003)
Therapeutic drug monitoring and phenotypic resistance testing are also found to be a valuable predictor of response.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Study of Tipranavir for First-Line Treatment Ends Early (June 9, 2006)
Newly released results from an industry-sponsored study make it doubtful that tipranavir will ever be used as first-line therapy.
From Boehringer Ingelheim